Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy

Nephrology
1
Pipeline Programs
1
Companies
1
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

SynAct Pharma
SynAct PharmaSweden - Lund
1 program
1
100 mg AP1189Phase 21 trial
Active Trials
NCT04456816Recruiting23Est. Jun 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
SynAct Pharma100 mg AP1189

Clinical Trials (1)

Total enrollment: 23 patients across 1 trials

A Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Treatment With AP1189 in Patients With iMN and Severe Proteinuria

Start: Aug 2020Est. completion: Jun 202623 patients
Phase 2Recruiting

Related Jobs in Nephrology

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 actively recruiting trials targeting 23 patients
1 companies competing in this space